NK150460 is a potent and selective inhibitor of breast cancer cells via activation the aryl hydrocarbon receptor (AhR) pathway.
NK150460 inhibits growth of not only most ER-positive, but also some ER-negative breast cancer cell lines, while never inhibiting growth of non-breast cancer cell lines.
NK150460 inhibits 17β-estradiol (E2)-dependent transcription without affecting binding of E2 to ER.
NK150460 does not induce histone H2AX phosphorylation or p53 expression.
NK150460 is a a novel AhR agonist dependent on AhR/ARNT and cytochrome P450 CYP1A1.
